Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | PTAFR | P25105 | 3/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651371 | 1.00 | ALDH1A1 (0.49) | ALDH1A1PTAFRNR3C1ACHEMAPK3 | |
| SCHEMBL4973283 | 0.88 | ALDH1A1 (0.38) | ALDH1A1PTAFRACHEMAPK3MAPK1 | |
| SCHEMBL4973278 | 0.88 | ALDH1A1 (0.38) | ALDH1A1PTAFRACHEMAPK3MAPK1 | |
| SCHEMBL5654177 | 0.87 | ALDH1A1 (0.37) | ALDH1A1PTAFRACHEMAPK3MAPK1 | |
| SCHEMBL5654176 | 0.87 | ALDH1A1 (0.37) | ALDH1A1PTAFRACHEMAPK3MAPK1 | |
| SCHEMBL4157984 | 0.80 | SLC6A2 (0.42) | ALDH1A1 | |
| SCHEMBL4176881 | 0.80 | SLC6A2 (0.42) | ALDH1A1 | |
| SCHEMBL4165135 | 0.80 | SLC6A2 (0.42) | ALDH1A1 | |
| SCHEMBL4973947 | 0.78 | LMNA (0.45) | ALDH1A1KDM4E | |
| SCHEMBL4973937 | 0.78 | LMNA (0.45) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | claimed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | ALDH1A1 416/4885PTAFR 3917/4885NR3C1 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.